Aligos Therapeutics

Focus: Aligos Therapeutics is a South San Francisco-based biotech focused on therapies for hepatologic diseases and viral infections, currently in early-stage clinical development with no marketed products.

Infectious Diseases Gastroenterology

Profile data last refreshed 15h ago · AI intelligence enriched 2w ago

Open Jobs

About Aligos Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Aligos Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

9 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

Pevifoscorvir

Chronic Hepatitis B Infection

Early Development

Lead program with 5 active trials in Phase 2; represents the company's most advanced clinical candidate.

Pipeline & Clinical Trials

ALG-097558

COVID-19

Phase 1

Help build intelligence for Aligos Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline in high-unmet-need areas: chronic hepatitis B (3 Phase 1 programs + 1 Phase 2), NASH (Phase 2), and COVID-19 (Phase 1) provide multiple clinical readout opportunities
Early-stage company structure offers flatter hierarchy and direct impact on drug development decisions for scientists and clinical professionals
Located in South SF biotech hub with proximity to talent pool, investors, and collaboration networks

Watch Out For

Zero active job openings at time of analysis signals potential hiring freeze, layoff, or transition phase—stability uncertain
Pre-revenue stage with unknown funding and cash runway creates burn-rate risk; no visibility into financial health or Series funding timelines
Early pipeline (11 Phase 1 programs, only 2 Phase 2) means 7+ years to potential first approval; long clinical de-risking period with no near-term catalysts

Generated by Claude from Aligos Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Clinical Trials (3)

NCT06698549A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal Function

Phase 1

NCT05840952A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558

Phase 1

NCT06568861A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Phase 1

ALG-125755

Chronic Hepatitis B

Phase 1

Clinical Trials (1)

NCT05561530A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects

Phase 1

ALG-020572

Chronic Hepatitis B

Phase 1

Clinical Trials (1)

NCT05001022A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects

Phase 1

ALG-010133

Chronic Hepatitis B

Phase 1

Clinical Trials (1)

NCT04485663A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

Phase 1

Carbamazepine

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT06672900A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers

Phase 1

ALG-000184

Chronic Hepatitis B

Phase 1

Clinical Trials (1)

NCT04536337A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

Phase 1

pevifoscorvir

Chronic Hepatitis B Infection

Phase 2

Clinical Trials (2)

NCT07342881Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function

Phase 1

NCT07342868Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Phase 1

ALG-055009

NASH - Nonalcoholic Steatohepatitis

Phase 2

Clinical Trials (4)

NCT06342947ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)

Phase 2

NCT06959888A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations

Phase 1

NCT05090111A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia

Phase 1

+1 more

ALG-000184

Chronic Hepatitis B Infection

Phase 2

Clinical Trials (1)

NCT06963710A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 15 clinical trials

Top TAs: Infectious Diseases, Metabolic Diseases

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Infectious Diseases

11 pipeline

Metabolic Diseases

1 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Private Funding (SEC Form D)

Jan 2020